ADMA Biologics, Inc. (NASDAQ:ADMA – Get Rating) has been given a consensus recommendation of “Buy” by the seven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $5.70.
ADMA has been the subject of several analyst reports. StockNews.com initiated coverage on shares of ADMA Biologics in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research upgraded shares of ADMA Biologics from a “sell” rating to a “hold” rating in a research note on Wednesday, April 27th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Telemetry Investments L.L.C. acquired a new position in ADMA Biologics in the 3rd quarter valued at approximately $68,000. Geode Capital Management LLC increased its stake in shares of ADMA Biologics by 24.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,313,094 shares of the biotechnology company’s stock valued at $1,483,000 after acquiring an additional 259,767 shares in the last quarter. First Hawaiian Bank acquired a new position in ADMA Biologics during the 4th quarter worth approximately $724,000. Credit Suisse AG bought a new position in shares of ADMA Biologics in the third quarter valued at $40,000. Finally, Altium Capital Management LP purchased a new stake in shares of ADMA Biologics in the third quarter worth approximately $4,653,000. Hedge funds and other institutional investors own 55.15% of the company’s stock.
ADMA Biologics (NASDAQ:ADMA – Get Rating) last issued its quarterly earnings results on Thursday, March 24th. The biotechnology company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The firm had revenue of $26.38 million during the quarter, compared to analysts’ expectations of $26.00 million. ADMA Biologics had a negative return on equity of 61.23% and a negative net margin of 88.51%. During the same period in the prior year, the firm posted ($0.20) earnings per share. On average, sell-side analysts expect that ADMA Biologics will post -0.31 EPS for the current year.
ADMA Biologics Company Profile (Get Rating)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
- Get a free copy of the StockNews.com research report on ADMA Biologics (ADMA)
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Knight-Swift Transportation Stock is a Logistics Winner
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.